ProCE Banner Activity

Venetoclax/Daratumumab/Dexamethasone ± Bortezomib in Patients With R/R MM: Initial Analysis of a Phase I/II Trial

Slideset Download
Conference Coverage
In patients with R/R MM, the combination of venetoclax/daratumumab/dexamethasone, with or without bortezomib, showed an acceptable safety profile and promising response rate.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Celgene

Dova Pharmaceuticals

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Karyopharm Therapeutics

Loxo Oncology subsidiary of Eli Lilly

Pharmacyclics an AbbVie Company